Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.49 |
| ▸ | HSP90AB1 | P08238 | 3/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | GHSR | Q92847 | 1/20 | 0.44 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | PLAU | P00749 | 2/20 | 0.41 |
| ▸ | PLAT | P00750 | 2/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | F10 | P00742 | 1/20 | 0.41 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.41 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4482255 | 0.84 | SLC6A2 (0.53) | KEAP1HSP90AA1HSP90AB1TP53TSHR | |
| SCHEMBL143826 | 0.84 | TP53 (0.65) | KEAP1HSP90AA1HSP90AB1TP53TSHR | |
| SCHEMBL3442604 | 0.83 | KEAP1 (0.49) | KEAP1HSP90AA1HSP90AB1TP53TSHR | |
| SCHEMBL2941369 | 0.81 | HPGD (0.56) | KEAP1HSP90AA1HSP90AB1TP53TSHR | |
| SCHEMBL1706516 | 0.79 | MMP2 (0.55) | KEAP1HSP90AA1HSP90AB1TP53TSHR | |
| SCHEMBL3309142 | 0.79 | ALB (0.55) | KEAP1HSP90AA1HSP90AB1TP53TSHR | |
| SCHEMBL7217634 | 0.79 | GHSR (0.47) | KEAP1HSP90AA1HSP90AB1TP53TSHR | |
| SCHEMBL3558867 | 0.79 | TSHR (0.47) | KEAP1HSP90AA1HSP90AB1TP53TSHR | |
| SCHEMBL29822323 | 0.77 | TP53 (0.69) | KEAP1HSP90AA1HSP90AB1TP53TSHR | |
| SCHEMBL610480 | 0.77 | TP53 (0.69) | KEAP1HSP90AA1HSP90AB1TP53TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190218219-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | INTRA-CELLULAR THERAPIES, INC. (US) | 2019-07-18 | — | — | US | claimed |
| US-20230009130-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | INTRA-CELLULAR THERAPIES, INC. | 2023-01-12 | — | — | US | disclosed |
| US-20220064166-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | INTRA-CELLULAR THERAPIES, INC. | 2022-03-03 | — | — | US | disclosed |
| US-11066407-B2 | Preparation of certain substituted 1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalines and pharmaceutically acceptable salts thereof | INTRA-CELLULAR THERAPIES, INC. (US) | 2021-07-20 | — | — | US | disclosed |
| EP-3663294-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | Intra-Cellular Therapies, Inc. (US) | 2020-06-10 | — | — | EP | disclosed |
| US-20200115380-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | INTRA-CELLULAR THERAPIES, INC. (US) | 2020-04-16 | — | — | US | disclosed |
| US-20200102309-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | INTRA-CELLULAR THERAPIES, INC. | 2020-04-02 | — | — | US | disclosed |
| US-10597395-B2 | Preparation of certain substituted 1-(4-fluorophenyl)-4-(2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-YL)butan-1-ones and pharmaceutically acceptable salts thereof | INTRA-CELLULAR THERAPIES, INC. (US) | 2020-03-24 | — | — | US | disclosed |
| US-20200087305-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | INTRA-CELLULAR THERAPIES, INC. (US) | 2020-03-19 | — | — | US | disclosed |
| EP-3609891-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | Intra-Cellular Therapies, Inc. (US) | 2020-02-19 | — | — | EP | disclosed |
| US-8309722-B2 | Substituted heterocycle gamma-carbolines synthesis | INTRA-CELLULAR THERAPIES, INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-7812024-B2 | Modulators of serotonin receptors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-10-12 | — | — | US | disclosed |
| US-20100113781-A1 | SUBSTITUTED HETEROCYCLE GAMMA-CARBOLINES SYNTHESIS | INTRACELLULAR THERAPIES, INC. (US) | 2010-05-06 | — | — | US | disclosed |
| EP-2134710-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | Intra-Cellular Therapies, Inc. (US) | 2009-12-23 | — | — | EP | disclosed |
| WO-2008112280-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | INTRA-CELLULAR THERAPIES, INC. (US) | 2008-09-18 | — | — | WO | disclosed |
| US-20070213337-A1 | MODULATORS OF SEROTONIN RECEPTORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-09-13 | — | — | US | disclosed |
| US-7244843-B2 | Modulators of serotonin receptors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-17 | — | — | US | disclosed |
| EP-1675859-A1 | MODULATORS OF SEROTONIN RECEPTORS | Bristol-Myers Squibb Company (US) | 2006-07-05 | — | — | EP | disclosed |
| WO-2005035533-A1 | MODULATORS OF SEROTONIN RECEPTORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-04-21 | — | — | WO | disclosed |
| US-20050080074-A1 | Modulators of serotonin receptors | BRISTOL-MYERS SQUIBB COMPANY | 2005-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190218219-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | CYCS, HCCS, IDH3B | KEAP1 2112/4885HSP90AA1 3213/4885HSP90AB1 3249/4885 |
| US-20200102309-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | HCCS, CYCS, CBR3 | KEAP1 2506/4885HSP90AA1 3102/4885HSP90AB1 3206/4885 |
| US-20100113781-A1 | SUBSTITUTED HETEROCYCLE GAMMA-CARBOLINES SYNTHESIS | CYCS, HCCS, CBR3 | KEAP1 1855/4885HSP90AA1 3123/4885HSP90AB1 3180/4885 |
| US-20070213337-A1 | MODULATORS OF SEROTONIN RECEPTORS | HTR5A, HTR1A, HTR2A | KEAP1 2712/4885HSP90AA1 3657/4885HSP90AB1 3778/4885 |
| US-20230009130-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | HCCS, CYCS, CBR3 | KEAP1 2506/4885HSP90AA1 3102/4885HSP90AB1 3206/4885 |
| US-10597395-B2 | Preparation of certain substituted 1-(4-fluorophenyl)-4-(2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-YL)butan-1-ones and pharmaceutically acceptable salts thereof | CYP3A7, CYP4B1, CYP1B1 | KEAP1 644/4885HSP90AA1 4345/4885HSP90AB1 4007/4885 |
| US-11066407-B2 | Preparation of certain substituted 1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalines and pharmaceutically acceptable salts thereof | CYP2F1, CYP3A4, CYP4F2 | KEAP1 765/4885HSP90AA1 4616/4885HSP90AB1 4546/4885 |
| US-20200087305-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | HCCS, CYCS, CBR3 | KEAP1 2339/4885HSP90AA1 3072/4885HSP90AB1 3182/4885 |
| US-20050080074-A1 | Modulators of serotonin receptors | HTR5A, HTR1A, HTR2B | KEAP1 3150/4885HSP90AA1 3330/4885HSP90AB1 3397/4885 |
| US-20220064166-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | HCCS, CYCS, CBR3 | KEAP1 2506/4885HSP90AA1 3102/4885HSP90AB1 3206/4885 |
| US-20200115380-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | HCCS, CYCS, CBR3 | KEAP1 2339/4885HSP90AA1 3072/4885HSP90AB1 3182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.